ESPR — Esperion Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $920.39m
- $1.43bn
- $332.31m
Annual cashflow statement for Esperion Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -144 | -269 | -234 | -209 | -51.7 |
| Depreciation | |||||
| Non-Cash Items | 62.1 | 57.2 | 61.7 | 59.9 | 88.6 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -4.26 | -52.5 | -3.37 | 13.7 | -60.5 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -85.2 | -264 | -175 | -135 | -23.7 |
| Capital Expenditures | -13.4 | 0 | — | — | -0.317 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 34.7 | -50.5 | 8.1 | 42.5 | 0 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 21.4 | -50.5 | 8.1 | 42.5 | -0.317 |
| Financing Cash Flow Items | -29.9 | 45.8 | -58.2 | -15.5 | -54.5 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 202 | 268 | 32.6 | 50.5 | 86.5 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 138 | -46.1 | -134 | -42.5 | 62.5 |